Reata Pharmaceuticals, Inc.
NEWS
Reata Pharmaceuticals was acquired by Biogen Inc. in September 2023.
The FDA said that the shared NDA documents did not show ample proof that bardoxolone methyl effectively slows down kidney function loss in patients with Alport syndrome.
The end of February picks up significantly from early this year for the U.S. Food and Drug Administration and its PDUFA dates.
Shares of Reata Pharmaceuticals have plunged nearly 40% in premarket trading after an FDA advisory panel recommended against the approval of its Alport syndrome disease treatment, bardoxolone.
In the staff documents, the FDA scientists expressed concerns over the Reata clinical data that was submitted.
The U.S. Food and Drug Administration is wrapping up 2021 with a fairly busy schedule for the month of December. Here’s a look at the first half of the month.
BioLabs is opening its next hub in Dallas in a 37,000-square-foot flexible life science facility. The Biotech+ Hub can accommodate 35 startups, for which it’s now accepting applications.
Texas-based Reata Pharmaceuticals announced the potential delay Monday when it released its 2nd quarter financial report.
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.
JOBS
IN THE PRESS